Claims for Patent: 4,694,007

Summary for Patent: 4,694,007

Title:	Use of trimetrexate as antiparasitic agent
Abstract:	A method of treating infections of Toxoplasmosis or P. carini comprising administering to the host an effective amount of trimetrexate, (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline.
Inventor(s):	Allegra; Carmen (Vienna, VA), Drake; James C. (Ijamsville, MD), Chabner; Bruce A. (Potomac, MD), Masur; Henry (Bethesda, MD), Kovacs; Joseph A. (Bethesda, MD)
Assignee:	The United States of America as represented by the Secretary of the (Washington, DC)
Application Number:	06/865,055
Patent Claims:	1. A method for treating infections of Toxoplasmosis or P. carinii comprising administering to a mammelian host in need of said treatment an amount of trimetrexate effective to treat said Toxoplasmosis or P. carinii. 2. The method of claim 1 wherein the trimetrexate is administered orally. 3. The method of claim 1 wherein the trimetrexate is administered in a dosage of about 30 mg/kg. 4. The method of claim 1 wherein the trimetrexate is administered in combination with leucovorin. 5. A method of inhibiting dihydrofolate reductase production by T. gondii or P. carinii in a mammalian host comprising administering to said mammalian host an amount of trimetrexate effective to inhibit said dihydrofolate reductase production.